Logo
x

Search

Subscribe Now

Cervical Cancer

Disease of the Month: Cervical Cancer

Disease of the Month: Cervical Cancer

  • January 12, 2023
Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer

Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer

  • October 25, 2021
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Second Indication in Cervical Cancer

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Second Indication in Cervical Cancer

  • October 14, 2021
Seagen and Genmab's Tivdak (tisotumab vedotin-tftv) Receive the US FDA's Accelerated Approval for the Treatment of Recurrent or Metastatic Cervical Cancer

Seagen and Genmab's Tivdak (tisotumab vedotin-tftv) Receive the US FDA's Accelerated Approval for the Treatment of Recurrent or Me...

  • September 22, 2021
Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-826 Trial as 1L Treatment for Cervical Cancer

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-826 Trial as 1L Treatment for Cervical Cancer

  • September 20, 2021
Regeneron and Sanofi Present Positive Results of Libtayo (cemiplimab) from P-III Trial for Cervical Cancer at ESMO2021

Regeneron and Sanofi Present Positive Results of Libtayo (cemiplimab) from P-III Trial for Cervical Cancer at ESMO2021

  • May 13, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.